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106Objective: To evaluate the effect of luteal phase support (LPS) in intrauterine insemination (IUI) cycles stimulated with gonadotropins.
Design: Randomized multicenter trial.
Setting: Academic tertiary care centers and afﬁliated secondary care centers.
Patient(s): Three hundred and ninety-three normo-ovulatory patients, <43 years, with body mass index%30 kg/m2, in their ﬁrst IUI
cycle, with at least one patent tube, a normal uterine cavity, and a male partner with total motile sperm count R5 million after
capacitation.
Intervention(s): Gonadotropin stimulation, IUI, randomization to LPS using vaginal progesterone gel (n ¼ 202) or no LPS (n ¼ 191).
Main Outcome Measure(s): Clinical pregnancy rate, live-birth rate, miscarriage rate, and duration of the luteal phase.
Result(s): The primary outcome, the clinical pregnancy rate, was not statistically different between the treatment group (16.8%) and
the control group (11%) (relative risk [RR] 1.54; 95% conﬁdence interval [CI], 0.89–2.67). Similarly, the secondary outcome, the live-
birth rate, was 14.9% in the treatment group and 9.4% in the control group (RR 1.60; 95% CI, 0.89–2.87). The mean duration of the luteal
phase was about 2 days longer in the treatment group (16.6  2.2 days) compared with the control group (14.6  2.5 days) (mean
difference 2.07; 90% CI, 1.58–2.56).
Conclusion(s): Although a trend toward a higher clinical pregnancy rate as well as live-birth rate was observed in the treatment group,
the difference with the control group was not statistically signiﬁcant.
Clinical Trial Registration Number: NCT01826747. (Fertil Steril 2016;-:-–-. 2016 by American Society for Reproductive
Medicine.)
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235I ntrauterine insemination (IUI) is generally perceived as aninfertility therapy with relatively low cost, low burden,and easy access. Gonadotropin stimulation combined
with IUI has been proven to be effective for several indications
including unexplained infertility, mild male infertility, and
minimal–mild endometriosis (1–4).
The luteal phase is deﬁned as the period between ovula-
tion and the end of the menstrual cycle, marked by the onset
of menses or establishment of a pregnancy (5). Normal luteal
function requires optimal preovulatory follicular develop-
ment, proper luteinization of the granulosa cells to produce
progesterone, continued tonic luteinizing hormone (LH) sup-
port, vascularization of the corpus luteum, and estrogen to
induce progesterone receptors in the endometrium (5).
Ovarian stimulation with gonadotropins in the context of
assisted reproductive technology (ART) is associated with
luteal phase deﬁciency, which can be compensated by hor-
monal luteal phase support (LPS) (6). During a fresh ART cy-
cle, deﬁciency in LPS is caused by the combination of
hormone stimulation with gonadotropins, pituitary inhibi-
tion of LH and follicle-stimulating hormone (FSH) secretion
with gonadotropin-releasing hormone (GnRH) agonists or
antagonists, and follicular granulosa cell aspiration during
egg retrieval, possibly impairing progesterone secretion
from the corpus luteum. In contrast, hormone stimulation
during an IUI cycle is typically performed with a lower
dose of gonadotropins, without pituitary inhibition of LH
or FSH secretion, and without follicular granulosa cell aspi-
ration. The question thus remains as to whether mild ovarian
stimulation with gonadotropins before IUI inﬂuences corpus
luteum function and thus whether LPS is needed in these
cycles.
The most common method of LPS in ART is vaginal
administration of progesterone because of its neutrality
regarding risk for ovarian hyperstimulation syndrome (7)
and its ease of administration when compared with intra-
muscular injections of progesterone. So far, it is not clear
whether LPS with vaginal progesterone is useful for treating
possible luteal phase deﬁciencies after ovarian stimulation
with gonadotropins in an IUI cycle. There has been insufﬁ-
cient clinical evidence that this approach is associated with
an increased clinical pregnancy rate or live-birth rate
compared with no LPS. In a randomized study (8), LPS with
vaginal progesterone after ovarian stimulation and IUI
increased the pregnancy rate from 12.7% to 21.1% per cycle
and the live-birth rate from 9.3% to 17.4% per cycle. Howev-
er, that study could be criticized for its high spontaneous
conception rate between treatment cycles of 30%, the
absence of power calculation, and the absence of conceal-
ment of allocation (8).
In our randomized, multicenter study, we tested the
hypothesis that LPS with a vaginal progesterone gel after
hormone stimulation with low-dose gonadotropins is associ-
ated with a higher clinical pregnancy rate (primary outcome
variable) when compared with a control group who received
no LPS. In addition, we documented the live-birth rate, miscar-
riage rate, and duration of luteal phase (number of days) as
relevant secondary outcome variables.
ORIGINAL ARTICLE: INFERTILITY2
FLA 5.4.0 DTD  FNS30424_prooMATERIALS AND METHODS
Patients
Between April 2011 and January 2015we conducted an open-
label, multicenter, randomized clinical trial (RCT) in nine
participating sites in Belgium. The study protocol and
informed consent form were approved by the institutional re-
view board of the coordinating center (Leuven University
Hospitals) (ML7232). This RCT was registered at Clinical-
Trials.gov (NCT01826747) and as EudraCT number 2010-
023867-17 (trial registration date: November 10, 2010; date
of ﬁrst patient's enrollment: April 2011).
All couples with an indication for IUI such as unexplained
infertility, mild male factor infertility, or minimal–mild endo-
metriosis were eligible for this study during their ﬁrst IUI cy-
cle. Before their inclusion in the study, all couples underwent
a complete infertility evaluation, including a medical history,
physical examination, serum hormone assays between days 2
and 5 of the menstrual cycle, pelvic ultrasound, assessment of
tubal patency either by hysterosalpingography or laparos-
copy, and semen analysis. Only normo-ovulatory patients
<43 years old, with a body mass index %30, with at least
one patent tube on hysterosalpingography and/or laparos-
copy, with a normal uterine cavity, and with a partner whose
sperm analysis showed a total motile sperm count of R5
million after capacitation were included.
Study Design
Eligible patients started gonadotropin stimulation only after
informed consent had been obtained. Patients were random-
ized either before or during the stimulation period but before
IUI was performed to receive either progesterone 8% vagi-
nally or no LPS. Patients were randomized per block of 10 pa-
tients and per center through an Internet-based
randomization system designed by the information technol-
ogy department at Leuven University Hospital and managed
by the Leuven University Fertility Center. Researchers were
blinded to group allocations. Before the start of the study,
the participating centers each received a center-speciﬁc login
and password that granted access to the randomization Web
site.
For days 2 to 3 of the menstrual cycle, the patients were
prescribed 37.5–75.0 IU recombinant FSH (Gonal-F; Merck
KGaA) to prevent multifollicular development of>2 follicles.
In the absence of follicular growth (absence of follicles
>10 mm) after 5 to 7 days, the dosage of the gonadotropins
was increased by 37 IU.
Monitoring of the cycle was according to site-speciﬁc
customs, with ultrasound and/or hormone analysis. Ovula-
tion was triggered with recombinant human chorionic gonad-
otropin (rhCG, Ovitrelle; Merck KGaA) when a maximum of
two dominant follicles was present. The IUI procedure was
planned for between 32 and 40 hours after hCG administra-
tion or 24–26 hours after detection of a spontaneous LH
surge. Both ultrasound and analysis of estradiol, LH, FSH,
and progesterone were performed on the day of planning of
the IUI (day of hCG administration or day of LH surge). Cycle
cancellation or ovarian follicle aspiration followed by IUI wasVOL.- NO.- /- 2016
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5TABLE 1
Baseline clinical characteristics per patient in intrauterine
insemination study with and without luteal phase support.
Variable
Control group
(n[ 191)a
Study group
(n[ 202)a
Mean female age  SD (y) 31.5  3.8 31.0  3.97
Mean BMI  SD (kg/m2) 23.0  3.2 23.2  3.4
Mean cycle duration  SD (d) 28.9  2.4 28.9  2.2
Type of infertility, no. (%)
Primary 120 (63%) 143 (71%)
Secondary 70 (37%) 58 (29%)
Duration of infertility  SD (mo)
Primary 28.6  20.0 26.5  19.7
Secondary 27.0  18.4 26.8  16.3
Indication for treatment, no. (%)
Anovulation 3 (2%) 7 (4%)
Endometriosis 16 (8%) 20 (10%)
Male factor 66 (35%) 77 (38%)
Mixed 43 (23%) 38 (19%)
Tubal factor 7 (4%) 3 (2%)
Unexplained 55 (29%) 56 (28%)
Note: BMI ¼ body mass index; SD ¼ standard deviation.
a One missing value.
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347advised when R3 dominant follicles of R15 mm were de-
tected to prevent high-order multiple pregnancies (9, 10).
Sperm preparation was performed according to local vali-
dated procedures. The patients were advised to rest in the su-
pine position during 15 minutes immediately after IUI
according to evidence from the literature (11).
In the control group, no LPS was provided. In the study
group, LPS was provided with progesterone 8% vaginal gel
(Crinone; Merck KGaA) once daily in the morning starting
on the day after IUI until the time of pregnancy test (b-
hCG) about 15 days after IUI. Crinone was administered by
an applicator that delivered 1.125 g of vaginal gel containing
90 mg of progesterone. Clinical pregnancy was deﬁned as the
presence of an intrauterine or extrauterine fetus with positive
heartbeat, on ultrasound at 6 to 8 weeks of amenorrhea (12).
Live birth was deﬁned as the live birth of a child beyond
24 weeks of gestation. Multiple live birth was deﬁned as the
birth of two or more infants.
Follow-up observation of the pregnancies and deliveries
was performed in the hospitals from the participating centers
and in other hospitals where the patients were referred for
their obstetric care. Although there was no speciﬁc study pro-
tocol for follow-up observation of the pregnancies in our
study, the clinical and obstetric data were systematically re-
ported in a standardized way according to the requirements
of the Belgian Register for Assisted Procreation (BELRAP),
in line with the compulsory registration of IUI cycles in
Belgium (13, 14).348
349
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354Clinical Outcome Parameters
The primary outcome was clinical pregnancy rate per ran-
domized cycle (positive ultrasound with gestational sac and
at least one fetal heartbeat detected by ultrasound at 7–
8 weeks of amenorrhea). The secondary outcomes includedVOL.- NO.- /- 2016
FLA 5.4.0 DTD  FNS30424_proolive-birth rate, miscarriage rate, and duration of luteal phase
between the day of hCG administration or LH peak and the
ﬁrst day of the next menstrual cycle in the absence of preg-
nancy. In a subanalysis, we compared the clinical pregnancy
and live-birth rates in cycles with monofollicular and multi-
follicular responses, respectively.Statistical Methods
Sample size calculation. Our objective was to test the hy-
pothesis that when compared with no LPS, LPS with a vaginal
progesterone gel leads to a higher clinical pregnancy rate (pri-
mary outcome) in a program of IUI after controlled ovarian
stimulation with gonadotropins. We based our power calcula-
tion on a randomized study (8) in patients treated with IUI af-
ter ovarian stimulation with gonadotropins that obtained a
clinical pregnancy rate of 21% in the study group with LPS
with vaginal progesterone and 13% in the control group
without LPS, resulting in a delta of 8%. In our study, assuming
a delta of 10% at a power of 80%, with double-sided alpha at
5%, we calculated a sample size of 502 patients at the initia-
tion of the study. Due to disappointing accrual, the study was
stopped after 4 years of recruitment, with a total 393 patients
included.
Statistical considerations. After randomization, an
intention-to-treat analysis was performed for all cycles
from all participating centers. The summary statistics are
presented as mean and standard deviation (SD) for contin-
uous variables, and as frequencies and percentages for cate-
gorical variables. Fisher exact and independent t test were
used to compare the categorical and continuous variables,
respectively, between the control cycles and LPS-treated cy-
cles. Treatment effects on binary outcomes were analyzed
using Poisson models with log link and are presented as rela-
tive risk (RR) with 95% conﬁdence interval (CI). Treatment
effects on continuous outcomes were analyzed using linear
models and are presented as mean differences with 95%
CI. Random intercepts were modeled in all outcome analyses
to account for clustering by center. One-sided P values were
reported for all outcome analyses. A 5% statistical signiﬁ-
cance level was assumed for all tests. A complete-case anal-
ysis was performed for the duration of the luteal phase,
excluding patient records with pregnancy and records with
missing observations (Table 3). QAll analyses were performed
using SAS software (version 9.4 for Windows; SAS
Institute).RESULTS
Between April 2011 and January 2015, 393 couples were ran-
domized to the study group with LPS (n ¼ 202) or the control
group (n ¼ 191) (Fig. 1). Both groups were comparable with
respect to baseline clinical characteristics (Table 1) and IUI cy-
cle parameters (gonadotropin dose, number of dominant fol-
licles, number of cycles with selective follicular aspiration
before IUI, sperm quality, endometrial thickness, and serum
estradiol level at time of hCG injection) (Table 2). The propor-
tion of women (in total 12 of 393 or 3% of all randomized3
f  23 August 2016  3:05 pm  ce E
TABLE 2
Intrauterine insemination cycle characteristics in study with and without luteal phase support.
Variable
Control group
(177 cycles)
Study group
(187 cycles) P value
Total motile sperm count after capacitation, mean (95% CI) (million) 28.2 (23.3; 33.2) 28.2 (23.4; 33.1) .998
Endometrial thickness (mm) at the time of hCG injection, mean (95% CI) 8.4 (8.2; 8.7) 8.6 (8.3; 8.8) .418
No. of dominant ovarian follicles with a diameterR14 mm at the time of
hCG injection, mean (95% CI)
1.2 (1.2; 1.3) 1.2 (1.1; 1.2) .119
Sperm origin, percentage of cycles using donor sperm (%) 8/177 (4.5%)a 9/187 (4.8%)a R.999
Selective ovarian follicular aspiration before IUI (%) 5/177 (2.8%)a 2/187 (1.1%)a .272
Serum 17b-estradiol level (pg/mL) at day of hCG administration, mean (95% CI) 311 (288; 334) 289 (266; 311) .173
Total dose of gonadotropins, mean (95% CI) 381 (351; 411) 390 (361; 419) .679
Monofollicular response, n/N (%) 135/177 (76.27%) 157/187 (83.96%) .086
Multifollicular response, n/N (%)b 42/177 (23.73%) 30/187 (16.04%)
Note: Unless otherwise indicated, data were analyzed using an independent t test. All reported P values are two-sided. CI ¼ conﬁdence interval; IUI ¼ intrauterine insemination; hCG ¼ human
chorionic gonadotropin.
a Analyzed using Fisher's exact test.
b More than one follicleR14 mm.
Peeraer. Luteal phase in IUI: support or not? Fertil Steril 2016.
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453cycles) who conceived spontaneously before the start of ther-
apy was similar in both groups (see Fig. 1).
The clinical pregnancy and live-birth rates did not show a
statistically signiﬁcant difference between the treatment
group (16.8% and 14.9%, respectively) and the control group
(11% and 9.4%, respectively) [RR 1.54; 95% CI, 0.89–2.67;
P¼ .12, and RR 1.60; 95% CI, 0.89–2.87; P¼ .12, respectively].
With an absolute risk difference of 6% (95% CI,0.05 to 0.18)
for pregnancy rate and 5% (95% CI, 0.05 to 0.16) for live-
birth rate, the number of patients needed to treat was 17 to
have one extra pregnancy, and 20 to achieve an extra live
birth. The miscarriage rates were similar in both treatment
(11.8%) and control (14.3%) groups (RR 0.8; 95% CI, 0.18–
3.8; P¼ .80). The mean duration of the luteal phase was about
2 days (mean difference 2.1 days; 95% CI, 1.58–2.56;
P< .0001) longer in the treatment group (16.6  2.2 days, n
¼ 137 cycles) compared with the control group (14.6 
2.5 days; n ¼ 133 cycles) (Table 3).
A subanalysis was performed according to the response to
ovarian stimulation to detect whether differences between the
study and control groups were related to the response toTABLE 3
Reproductive outcome per randomized cycle (intention-to-treat analysis)
Control group
Per randomized cycle 191 cycles
FHB þ pregnancy rate 21/191 (11%) 3
LBR per cycle 18/191 (9.4%) 3
Miscarriage rate 3/21 (14.3%)
133 cycles
Mean duration luteal phase (d): (SD) (95% CI) 14.6  2.5
Per IUI cycle 177 cycles
FHB þ pregnancy rate 17/177 (9.6%) 2
LBR per cycle 14/177 (7.9%) 2
Miscarriage rate 3/17 (17.7%)
Note: CI ¼ conﬁdence interval; FHB ¼ fetal heartbeat; IUI ¼ intrauterine insemination; LBR ¼ live-b
a Binary outcomes: relative risk with 95% CI þ P value (two-sided test; Poisson model with log-link
b Continuous outcome: mean differences with 95% CI þ P value (two-sided test).
Peeraer. Luteal phase in IUI: support or not? Fertil Steril 2016.
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FLA 5.4.0 DTD  FNS30424_prooovarian stimulation. Both the cycles with monofollicular
response (135 of 177; 76.3%) and multifollicular response
(>1 follicleR14 mm at the time of hCG injection) had com-
parable results. In cycles with a monofollicular response, the
clinical pregnancy rate was 14.01% and the live-birth rate
was 12.10% in the treatment group; this was comparable
with 8.15% and 6.67%, respectively, in the control group
(RR 1.75; 95% CI, 0.84–3.62; P¼ .133, and RR 1.85; 95% CI,
0.83–4.11; P¼ .130). In cycles with multifollicular response,
the clinical pregnancy rate was 16.67% and live-birth rate
was 13.33% in the treatment group; this was comparable
with 14.29% and 11.90%, respectively, in the control group
(RR 1.09; 95% CI, 0.32–3.75; P¼ .892, and RR 1.11; 95% CI,
0.29–4.27; P¼ .881). There were two dichorial diamniotic
twins in the study group (2 of 30; 7%) and none in the control
group (0 of 18).DISCUSSION
In this multicenter RCT, we did not conﬁrm the hypothesis
that LPS with a vaginal progesterone gel after hormoneand per intrauterine insemination cycle (per-protocol analysis) Q9.
Study group
Relative risk
(95% CI)
Absolute risk
differences %
(95% CI) P value
202 cycles
4/202 (16.8%) 1.54 (0.89; 2.67) 6.1 (5.4; 17.6) .12a
0/202 (14.9%) 1.60 (0.89; 2.87) 5.4 (4.7; 15.6) .12a
4/34 (11.8%) 0.8 (0.18; 3.8) 2.5 (22.4; 17.3) .80a
137 cycles Mean differences
16.6  2.2 2.07 (1.58; 2.56) < .0001b
187 cycles Relative risk
7/187 (14.4%) 1.52 (0.82; 2.79) 5.1 (4.4; 14.6) .18a
3/187 (12.3%) 1.57 (0.81; 3.07) 4.5 (3.6; 12.6) .18a
4/27 (14.8%) 0.84 (0.18; 3.892) 2.8 (27.5; 21.9) .82a
irth rate; SD ¼ standard deviation.
).
VOL.- NO.- /- 2016
f  23 August 2016  3:05 pm  ce E
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
67
FIGURE 1
393 Randomized cycles
202 Included in analysis191 Included in analysis
202 Randomized to study group with LPS (vaginal 
progesterone gel) 
187 Received intervention as randomized
15 Did not received intervention as randomized
 Spontaneous pregnancy: ( n=7)
 Medical reason ( thin endometrium, multifollicular 
response, premature LH peak): (n=3)
 Personal reason: (n=4)
 Protocol violation: (n=1)
191 Randomized to control group without LPS
177 Received intervention as randomized
14 Did not received intervention as randomized
 Spontaneous pregnancy: ( n=5)
 Medical reason (multifollicular response, insufficient 
ovarian response, luteal insufficientie, illness, no sperm 
for IUI due to masturbation problems): (n=6)
 Personal reason: (n=2)
 Protocol violation: (n=1)
159 Refused to participate 
552 Assessed for eligibility
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Consolidated Standards of Reporting Trials (CONSORT) diagram of screening, randomization, and follow-up observation of study participants.
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590stimulation with low-dose gonadotropins is associated with a
statistically signiﬁcant higher clinical pregnancy rate (fetal
heart rate positive) when compared with no administration
of LPS. The results should be interpreted recognizing that
the study ended up being underpowered to demonstrate
P< .05, and thus is not adequate to answer the research ques-
tion. However, because of the large size of the study, these
data can be used in future meta-analyses on this topic and
are therefore relevant. Miscarriage and live births were also
not affected. However, there was an absolute risk difference
for the clinical pregnancy rate of 6% and live-birth rate of
5% in the study group with LPS. The duration of the luteal
phase was statistically signiﬁcantly longer (about 2 days) in
the study group with LPS than in the control group without
LPS.
Our study is marked by several strengths. First, to the best
of our knowledge, it includes the highest number of patients
ever included in an RCT allowing only one cycle per patient
to test this hypothesis. Second, the randomization method
was objective and allowed stratiﬁcation per center (com-
puter-generated random allocation). Third, the data were
analyzed using an intention-to-treat approach. Fourth, the
duration of the luteal phase was investigated for the ﬁrst
time in an RCT. Our observation that the duration of the luteal
phase was 2 days longer in women receiving LPS with proges-
terone is novel but not surprising in view of the physiologic
action of progesterone on the estrogen-primed endometrium.
In view of the growing awareness of patient-centeredness in
fertility treatment and decision making (15), it is important
to inform the patient about this prolonged luteal phase, which
may be a burden in patients who are waiting for the outcome
of the treatment. Our hypothesis that most patients will accept
this inconvenience because luteal support is associated with a
statistically signiﬁcant higher clinical pregnancy rate requires
further investigation.VOL.- NO.- /- 2016
FLA 5.4.0 DTD  FNS30424_prooOur study is also marked by several limitations. First, the
open-label design and the absence of a placebo control group
represent possible sources of treatment bias. Second, the re-
sults are derived from a smaller sample size than initially in-
tended (78% of the initial sample size calculation); thus, the
study ended up being underpowered to demonstrate P< .05,
but the results are in line with similar studies that showed a
higher clinical pregnancy rate in the LPS group although
they were not statistically signiﬁcant (8, 16, 17).
The results of our study support other evidence from a
systematic review that showed improved reproductive out-
comes after LPS with progesterone in women treated with a
combination of gonadotropins and IUI (18). In a subanalysis
of this systematic review, the clinical pregnancy rate after
IUI improved after LPS with progesterone after ovarian stim-
ulation with gonadotropins (odds ratio [OR] 1.77; 95% CI,
1.2–2.6). QWe would like to point out that the RR 1.54 for clin-
ical pregnancy with LPS in our study is similar to the OR 1.77
for clinical pregnancy found in this meta-analysis. However,
it cannot be concluded that LPS with progesterone can
improve clinical pregnancy rates in any woman who receives
ovarian stimulation before IUI because no difference was
found after ovarian stimulation with clomiphene citrate
(CC) (OR 0.89; 95% CI, 0.47–1.67) Qor with a combination of
CC and gonadotropins (OR 1.34; 95% CI, 0.81–2.23). Accord-
ing to Hill et al. (18), this subanalysis suggests that endoge-
nous corpus luteum function may be decreased in
gonadotropin cycles and be normal or supported in CC cycles.
However, it is important to note that reproductive outcome
after IUI cycles is reported to be signiﬁcantly better after
ovarian stimulation with gonadotropins than after ovarian
stimulation with CC, even in the absence of LPS (4, 19).
It has been hypothesized that LPS after IUI is especially
beneﬁcial after ovarian stimulation with gonadotropins re-
sulting in multifollicular response, based on the assumption5
f  23 August 2016  3:05 pm  ce E
8ORIGINAL ARTICLE: INFERTILITY
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706that multifollicular response is associated with higher early
luteal phase estradiol levels secreted by multiple corpora lu-
tea, inhibiting via negative feedback pituitary LH secretion
required for optimal corpus luteum function (8, 17).
Although this hypothesis was not addressed in our study,
which used a relatively low starting rFSH dose, it was not
supported by our subanalysis showing a similar trend to
improved reproductive outcome after either monofollicular
or multifollicular response.
It is not clear whether the data from our study can be
extrapolated to other forms of luteal support after IUI, as there
is no consensus on the dose or type for luteal support in IUI
cycles (16, 18, 20). In our study, patients from the study
group applied a vaginal gel containing 8% of progesterone,
once a day, with a total dose of 90 mg per application. A
recent RCT (21) that demonstrated that clinical pregnancy
rate was not improved after LPS with 200 mg of vaginal
progesterone when compared with no LPS can be criticized
for its lack of power calculation, lack of intention-to-treat
analysis, high drop-out rates (10.6%), and patients potentially
being randomized several times without apparent control for
the presence of multiple measures in the statistical analysis. In
a dose-ﬁnding study (20), the ongoing clinical pregnancy rate
was similar after vaginal LPS with 300 mg or 600 mg of pro-
gesterone after ovarian stimulation with gonadotropins and
IUI, but that study lacked a power calculation as well. All ran-
domized trials on this issue lack power calculation, and it is
also not clear whether the hypothesis was tested two sided.
CONCLUSIONS
In conclusion, ourmulticenter study, the largest RCT testing the
hypothesis on the patient level, demonstrated that in patients
treated with IUI after ovarian stimulation with gonadotropins,
the clinical pregnancy rate was not statistically signiﬁcantly
higher after LPS with a vaginal progesterone gel (17%) than
in patients without LPS (11%). However, these data are derived
from a sample size smaller than intended with the initial power
calculation. The large sample size of our study and the similar
ﬁndings of the meta-analysis suggest there may be a beneﬁt of
supplementing the luteal phase in patients with an indication
for IUI stimulated with gonadotropins, independent of a mono-
follicular or multifollicular response.
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